Senti Biosciences (SNTI) Liabilities and Shareholders Equity (2021 - 2025)

Senti Biosciences has reported Liabilities and Shareholders Equity for 5 years, with the latest figure at $51.2 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 47.65% year-over-year to $51.2 million; the trailing twelve-month figure through Dec 2025 stood at $255.2 million (down 25.95% YoY), and the FY2025 full-year result was $51.2 million, down 47.65% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $51.2 million, down from $52.7 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $231.9 million in Q2 2021, with the low at $373657.0 in Q1 2021.
• Average Liabilities and Shareholders Equity over 5 years is $126.0 million, with a median of $110.8 million recorded in 2023.
• Year-over-year, Liabilities and Shareholders Equity soared 61698.89% in 2022 and tumbled 56.19% in 2024.
• Tracing SNTI's Liabilities and Shareholders Equity over 5 years: stood at $96.7 million in 2021, then soared by 86.96% to $180.8 million in 2022, then tumbled by 33.91% to $119.5 million in 2023, then decreased by 18.11% to $97.8 million in 2024, then sank by 47.65% to $51.2 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $51.2 million (Q4 2025), $52.7 million (Q3 2025), and $68.5 million (Q2 2025), per Business Quant data.

Peer Comparison